Neo-adjuvant Treatment for Squamous Cell Carcinoma Using Direct Tumor Injection With RP1.
Status:
Not yet recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1b, single-center, open-label study, evaluating efficacy and safety of RP1
for the treatment of resectable cutaneous Squamous Cell Carcinoma in up to 12 evaluable
patients. In this study, patients will receive RP1 via direct intratumoral (IT) injection
into superficial cutaneous solid tumors to assess the safety and tolerability as well
efficacy of RP1 treatment. The primary efficacy population is up to 12 evaluable patients
with resectable CSCC. The enrollment of patients with CSCC will determine study duration.